Evidence map›Paper›PMID 36108404›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022

Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assays.

Ran Zhuo, Carmen Charlton, Sabrina Plitt, L Alexa Thompson, Sheila Braun, Jacqueline Day, Carla Osiowy, Graham Tipples, Jamil N Kanji

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ran ZhuoPublic Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada. Electronic address: rzhuo@ualberta.ca.
Carmen CharltonPublic Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
Sabrina PlittSchool of Public Health, University of Alberta, Edmonton, Alberta, Canada; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
L Alexa ThompsonDepartment of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Sheila BraunPublic Health Laboratory, Alberta Precision Laboratories, Calgary, Alberta, Canada.
Jacqueline DayNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Carla OsiowyNational Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.; University of Manitoba, Winnipeg, MB, Canada.
Graham TipplesPublic Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
Jamil N KanjiPublic Health Laboratory, Alberta Precision Laboratories, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada; Public Health Laboratory, Alberta Precision Laboratories, Calgary, Alberta, Canada; Section of Medical Microbiology, Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
University of Alberta · CAAlberta Hospital Edmonton · CAPublic Health Agency of Canada · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The accurate measurement of serological response to SARS-CoV-2 vaccination is needed to correlate responses with effective protective immunity. The World Health Organization (WHO) has created an international standard to allow harmonization of immune response assessment to an arbitrary unit across different commercial assays; however, the accuracy of reporting of SARS-CoV-2 spike antibody titers in international standard units (BAU or IU/mL) from commercial assays is not well studied. Here, we report the performance comparison of four quantitative commercial assays testing for SARS-CoV-2 spike immunoglobins using the WHO's international standard. Sera, EDTA-plasma and heparinized plasma collected from individuals who are vaccine naïve or received BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna) or ChAdOx1-S (Oxford-AstraZeneca) were tested using Abbott Architect AdviseDx SARS-CoV-2 IgG II, DiaSorin LIAISON SARS-CoV-2 TrimericS IgG, Roche Elecsys Anti-SARS-CoV-2 S and GenScript cPass SARS-CoV-2 surrogate virus neutralization assays. The sensitivities ranged from 90% to 100%, and specificities from 88% to 100%. These four assays had excellent agreement (0.79-0.93) and correlation (0.87-0.97); however, Passing-Bablok regression analysis indicated that data generated by these assays were not comparable. Our data suggests that natural SARS-CoV-2 infection elicited a greater antibody response compared to vaccines, evident by a significantly higher neutralizing antibody titer in unvaccinated individuals who seroconverted.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesEdetic AcidHumansImmunoglobulin GSpike Glycoprotein, CoronavirusWorld Health OrganizationAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesEdetic AcidImmunoglobulin GSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2AntibodiesCOVID-19ImmunoglobulinQuantitative serological assaysSARS-CoV-2WHO international standard

Identifiers

PMID36108404
PMCPMC9444336
OpenAlexW4295835897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.